# Esperion Therapeutics, Inc. clinical trials: 24 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 24 trials with Esperion Therapeutics, Inc. as lead sponsor, 1 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Esperion Therapeutics, Inc.: 24 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/esperion-therapeutics-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 24
- Recruiting or not yet: 1
- Read on: November 19, 2026

## Trials

The 24 newest of 24, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 1, 2023 | NCT06021951 | Milk-Only Lactation Study to Evaluate the Concentration of Bempedoic Acid and Bempedoic Acid/Ezetimibe Fixed Combination Drug Product... | Esperion Therapeutics, Inc. | Phase 4 | Completed | Healthy Lactating Women | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06021951) |
| January 23, 2023 | NCT05694260 | A Clinical Study in Children With Heterozygous Familial Hypercholesterolemia (HeFH) Aged 6 to 17 Treated Once Daily With Bempedoic Acid... | Esperion Therapeutics, Inc. | Phase 2 | Completed | Hypercholesterolemia | 31 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05694260) |
| November 2, 2021 | NCT05103254 | Bempedoic Acid Pregnancy Surveillance Program | Esperion Therapeutics, Inc. | Observational | Recruiting | Pregnancy, Hyperlipidemias | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05103254) |
| May 22, 2018 | NCT03531905 | Bempedoic Acid + Ezetimibe Fixed-Dose Combination (FDC) Study in Patients With Type 2 Diabetes and Elevated LDL-C | Esperion Therapeutics, Inc. | Phase 2 | Completed | Diabetes, Diabetes Mellitus, Type 2, Cholesterolemia | 242 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03531905) |
| November 8, 2017 | NCT03337308 | A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe... | Esperion Therapeutics, Inc. | Phase 3 | Completed | Hyperlipidemias | 382 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03337308) |
| June 20, 2017 | NCT03193047 | Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg When Added to PCSK9 Inhibitor Therapy | Esperion Therapeutics, Inc. | Phase 2 | Completed | Hypercholesterolemia | 59 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03193047) |
| March 1, 2017 | NCT03067441 | Assessment of the Long-Term Safety and Efficacy of Bempedoic Acid (CLEAR Harmony OLE) | Esperion Therapeutics, Inc. | Phase 3 | Completed | Hypercholesterolemia, Atherosclerotic Cardiovascular Disease | 1,462 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03067441) |
| February 13, 2017 | NCT03051100 | Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg, Ezetimibe 10mg, and Atorvastatin 20 mg Triplet Therapy in... | Esperion Therapeutics, Inc. | Phase 2 | Completed | Hypercholesterolemia | 63 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03051100) |
| December 22, 2016 | NCT03001076 | Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR... | Esperion Therapeutics, Inc. | Phase 3 | Completed | Hypercholesterolemia, Atherosclerosis, Statin Adverse Reaction | 269 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03001076) |
| December 15, 2016 | NCT02993406 | Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant... | Esperion Therapeutics, Inc. | Phase 3 | Completed | Cardiovascular Diseases, Statin Adverse Reaction | 13,970 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02993406) |
| December 13, 2016 | NCT02991118 | Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk | Esperion Therapeutics, Inc. | Phase 3 | Completed | Hypercholesterolemia, Atherosclerotic Cardiovascular Disease | 779 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02991118) |
| December 9, 2016 | NCT02988115 | Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Intolerant | Esperion Therapeutics, Inc. | Phase 3 | Completed | Hypercholesterolemia, Atherosclerotic Cardiovascular Disease, Statin Adverse Reaction | 345 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02988115) |
| January 28, 2016 | NCT02666664 | Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony) | Esperion Therapeutics, Inc. | Phase 3 | Completed | Hypercholesterolemia, Atherosclerotic Cardiovascular Diseases | 2,230 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02666664) |
| January 20, 2016 | NCT02659397 | A Study Of Pharmacokinetics, Pharmacodynamics And Safety Of Adding ETC-1002 To Atorvastatin 80 mg | Esperion Therapeutics, Inc. | Phase 2 | Completed | Hyperlipidemia | 68 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02659397) |
| June 30, 2014 | NCT02178098 | Evaluation of ETC-1002 in Participants With Hypercholesterolemia and Hypertension | Esperion Therapeutics, Inc. | Phase 2 | Completed | Hypercholesterolemia, Hypertension | 143 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02178098) |
| February 26, 2014 | NCT02072161 | Evaluation of ETC-1002 vs Placebo in Patients Receiving Ongoing Statin Therapy | Esperion Therapeutics, Inc. | Phase 2 | Completed | Hypercholesterolemia | 133 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02072161) |
| January 24, 2014 | NCT02044627 | Single Radiolabeled Dose Study to Investigate the Absorption, Metabolism and Excretion of \[14C\]-ETC-1002 | Esperion Therapeutics, Inc. | Phase 1 | Completed | Hyperlipidemia | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02044627) |
| September 13, 2013 | NCT01941836 | Evaluation of ETC-1002, Ezetimibe, and the Combination in Hypercholesterolemic Patients | Esperion Therapeutics, Inc. | Phase 2 | Completed | Hypercholesterolemia | 349 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01941836) |
| January 30, 2013 | NCT01779453 | A Study of the Safety, Pharmacokinetic Drug Interaction and Efficacy of ETC-1002 and Atorvastatin in Subjects With Hypercholesterolemia | Esperion Therapeutics, Inc. | Phase 2 | Completed | Hypercholesterolemia | 58 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01779453) |
| December 18, 2012 | NCT01751984 | A Study of the Efficacy and Safety of ETC-1002 in Participants With Statin Intolerance | Esperion Therapeutics, Inc. | Phase 2 | Completed | Hypercholesterolemia | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01751984) |
| May 30, 2012 | NCT01607294 | A Single Center Study to Evaluate the Efficacy and Safety of ETC 1002 in Subjects With Type 2 Diabetes | Esperion Therapeutics, Inc. | Phase 2 | Completed | Hyperlipidemia, Type 2 Diabetes | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01607294) |
| December 5, 2011 | NCT01485146 | A Multiple Ascending Dose Study of ETC-1002 in Healthy Subjects | Esperion Therapeutics, Inc. | Phase 1 | Completed | Safety Evaluation of Escalating Doses | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01485146) |
| December 17, 2010 | NCT01262638 | A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated... | Esperion Therapeutics, Inc. | Phase 2 | Completed | Dyslipidemia | 177 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01262638) |
| April 16, 2010 | NCT01105598 | A Multiple Ascending Dose Study of ETC-1002 in Subjects With Mild Dyslipidemia | Esperion Therapeutics, Inc. | Phase 1 | Completed | Mild Dyslipidemia | 53 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01105598) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 3 |
| Phase 2 | 12 |
| Phase 3 | 7 |
| Phase 4 | 1 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 23 |
| Recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Hypercholesterolemia | 15 |
| Hyperlipidemias | 9 |
| Atherosclerosis | 6 |
| Hyperlipoproteinemia Type II | 2 |
| Diabetes Mellitus, Type 2 | 2 |
| Cardiovascular Diseases | 1 |
| Dyslipidemias | 1 |
| Diabetes Mellitus | 1 |
| Hypertension | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Fire and water damage restoration companies in the United States](https://specstream.ai/data/businesses/fire-and-water-damage-restoration-companies/united-states)
- [Biotechnology companies in the United States](https://specstream.ai/data/businesses/biotechnology-companies/united-states)
- [Telecommunications companies in the United States](https://specstream.ai/data/businesses/telecommunications-companies/united-states)
- [Obstetrics and gynecology practices in the United States](https://specstream.ai/data/businesses/obstetrics-and-gynecology-practices/united-states)
- [Forklift dealers in the United States](https://specstream.ai/data/businesses/forklift-dealers/united-states)
- [Builders in the United States](https://specstream.ai/data/businesses/builders/united-states)
